The jingle dress: The story behind a Native American dance and its power of spiritual healing

The Jingle Dress:  The story behind a Native American dance and its power of spiritual healing, ABC News

When the United States was hit with the influenza pandemic in 1918, the women of the Ojibwe tribe practiced a healing ritual known as "the jingle dress" dance. It is characterized by the tinkling sounds made by the silver cones that adorn the dress each time the dancer moves.....

Popular posts from this blog

The Concept of Treatment-Refractory Addiction: A Call to the Field

Not all patients respond to effective and approved treatment interventions, and there has been growing recognition in the medical field of these “resistant” or refractory illnesses (eg, treatment-resistant depression, resistant hypertension). In the field of substance use disorders, there has not been an explicit acknowledgement of treatment-refractory addiction (TRA) despite substantial evidence that many patients do not respond to standard-of-care treatment interventions. This article provides a justification for TRA as a critically important condition to recognize and define. TRA is not conceptualized as a diagnosis, but as a signal that a current treatment approach has not worked. The article addresses areas in need of research and consensus in order to ensure the approach to TRA is uniform, thoughtfully addressed, and data-driven. By explicitly acknowledging TRA, clinicians, researchers, and patients and their families can begin to explore the unique features of this population an...
Read more

Signaling-specific inhibition of the CB1 receptor for cannabis use disorder

Haney, M., Vallée, M., Fabre, S.  et al.  Signaling-specific inhibition of the CB 1  receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.  Nat Med   29 , 1487–1499 (2023). https://doi.org/10.1038/s41591-023-02381-w   AEF0117 significantly reduced cannabis’ positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo ( P  < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration ( P  < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.
Read more